The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study

Poetter-Lang, Sarah; Staufer, Katharina; Baltzer, Pascal; Tamandl, Dietmar; Muin, D; Bastati, Nina; Halilbasic, Emina; Hodge, Jacqueline C.; Trauner, Michael; Kazemi-Shirazi, Lili; Ba‐Ssalamah, Ahmed

doi:10.1007/s00330-018-5650-5

Cited by 19 publications

(20 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With multiparametric MRI, including T1 and T2, chemical shift imaging (CSI) as well as diffusion weighted imaging (DWI) and dynamic contrast-enhanced imaging, the anatomy and pathology of the liver and the biliary tree can be accurately assessed. [5][6][7] Furthermore, because of its high soft tissue contrast, MRI can even be performed without administration of contrast media in those patients with contraindications. Several methods have been described that quantify sarcopenia on cross-sectional imaging with the skeletal muscle index (SMI) being the most commonly used one.…”

Section: Introductionmentioning

confidence: 99%

“…However, MRI is increasingly used in the diagnostic workup of patients with CLD. With multiparametric MRI, including T1 and T2, chemical shift imaging (CSI) as well as diffusion weighted imaging (DWI) and dynamic contrast‐enhanced imaging, the anatomy and pathology of the liver and the biliary tree can be accurately assessed 5–7 . Furthermore, because of its high soft tissue contrast, MRI can even be performed without administration of contrast media in those patients with contraindications.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MRI‐defined sarcopenia predicts mortality in patients with chronic liver disease

Beer

Bastati

Ba‐Ssalamah

et al. 2020

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

MRI‐defined sarcopenia predicts mortality in patients with chronic liver disease

Beer

Bastati

Ba‐Ssalamah

et al. 2020

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

“…There is, however, not a single diagnostic test to screen all patients. Poetter‐Lang et al demonstrated 3 characteristics seen on magnetic resonance imaging (MRI) in CFLD, including the presence of altered gallbladder morphology, periportal tracking (a bandlike hyperintense signal alteration along the portal triad), and periportal fat deposition. Although these imaging features alone are not specific to CFLD and can be seen in any of the cholestatic liver diseases, in a patient with CF, they can be important markers for early detection for CFLD (Fig.…”

Section: Diagnosis Management and Treatment Of Liver Disease In Cfmentioning

confidence: 99%

“…Prospective assessment of the algorithm demonstrated a sensitivity and specificity of 94.1% and 84.6%, respectively, in the diagnosis of CFLD. (24) The variability in liver disease manifestation in CF contributes to the challenges in establishing a definition of CF-related liver disease. As a result, the criteria to define CFLD have not been clearly established.…”

Section: Diagnostic Criteria For Cfldmentioning

confidence: 99%

Cystic Fibrosis–Associated Liver Disease in Lung Transplant Recipients

Mallea¹,

Bolan²,

Cortese

et al. 2019

Liver Transpl

View full text Add to dashboard Cite

Cystic fibrosis (CF) is an autosomal recessive disease characterized by mutations in the gene that encodes for the cystic fibrosis transmembrane conductance regulator protein (CFTR). CFTR gene mutations manifest as epithelial cell dysfunction in the airways, biliary tract, pancreas, gut, sweat glands, paranasal sinuses, and genitourinary tract. The clinical manifestations of this dysfunction include respiratory tract infections, bronchiectasis, pancreatic insufficiency, malabsorption, intestinal obstruction, liver disease, and male infertility. The liver disease manifestations of CF can include biliary disease, multilobular cirrhosis, and portal hypertension with and without cirrhosis. Pulmonary disease is the main cause for morbidity and mortality in individuals with CF, and according to the International Society for Heart and Lung Transplantation, CF is the third most common indication for lung transplantation in adults, accounting for 16% of procedures performed. The survival after lung transplantation in individuals with CF continues to improve and is now the highest among end‐stage lung diseases requiring transplant. The survival rate at 10 years is close to 50%. Given the potential presence of liver disease in CF patients undergoing an evaluation for lung transplantation and in lung transplant recipients, it is important to understand the manifestations of liver disease in CF patients and the recommended workup and follow‐up. This review aims to discuss the current literature and provide guidance in the management of these patients.

show abstract

“…In this constellation imaging methods without radiation exposure should be chosen. Beside conventional ultrasonography also additional sonography methods like point shear wave elastography (pSWE) and MRI imaging, especially MR cholangiopancreatography (MRCP) may be eligible for this group of patients, both without radiation exposure [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic accuracy of MRI with MRCP and B-Mode-sonography with elastography of the pancreas in patients with cystic fibrosis: a point-to-point comparison

et al. 2019

View full text Add to dashboard Cite

ObjectiveFor patients with cystic fibrosis, the imaging of the pancreas is of crucial importance for the early detection of pancreatic carcinoma. Comparative studies between Magnetic Resonance Imaging (MRI) and sonographic pancreas sonography are not yet available. The aim of the study was to compare MRI, sonography and point-shearwave elastography (pSWE). A total of 19 patients were included (10 male, 9 female; age 29.7 ± 14.3 years) in the study. Ultrasonography with pSWE and contrast enhanced MRI with MRCP were performed.ResultsSignificant differences between measurements of pancreatic body were registered in MRI with 1.4 ± 0.6 cm vs 1.0 ± 0.4 cm in ultrasound (p = 0.049), however not for pancreatic head and tail. In 10/19 patients (52.6%) pancreatic parenchyma did not show in MRI because of complete lipomatous transformation, but could be detected in ultrasound. pSWE-values showed no significant differences between the full and partial fatty transformation in pancreatic head (p = 0.968), body (p = 0.657) and tail (p = 0.840). pSWE-values did not correlate with measured signal intensity in T1w flash (p = 0.930, r = 0.025) and T2w HASTE sequences (p = 0.152, r = − 0.375). In patients with CF ultrasound is superior to MRI for displaying full fibro-fatty parenchymal transformation, pancreatic duct. Ultrasound elastography did not provide additional clinical relevant information.Electronic supplementary materialThe online version of this article (10.1186/s13104-019-4193-4) contains supplementary material, which is available to authorized users.

show abstract

The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study

Cited by 19 publications

References 47 publications

MRI‐defined sarcopenia predicts mortality in patients with chronic liver disease

MRI‐defined sarcopenia predicts mortality in patients with chronic liver disease

Cystic Fibrosis–Associated Liver Disease in Lung Transplant Recipients

Diagnostic accuracy of MRI with MRCP and B-Mode-sonography with elastography of the pancreas in patients with cystic fibrosis: a point-to-point comparison

Contact Info

Product

Resources

About